New hope for rare lung cancer: experimental drug combo enters phase 2 trial
NCT ID NCT07476287
First seen Mar 17, 2026 · Last updated May 24, 2026 · Updated 7 times
Summary
This study tests a new medicine called PF-08634404, given with chemotherapy, for adults with transformed small cell lung cancer (T-SCLC), a rare and aggressive cancer that develops after other treatments stop working. About 40 participants who have not yet been treated for T-SCLC will receive the drug combination through IV infusions. The goal is to see how well the treatment shrinks tumors and to monitor any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER (SCLC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hope and Healing Clinical Research
RECRUITINGHinsdale, Illinois, 60521, United States
-
Hope and Healing Clinical Research
RECRUITINGNew Lenox, Illinois, 60451, United States
-
Japanese Foundation for Cancer Research
NOT_YET_RECRUITINGKotoku, Tokyo, 135-8550, Japan
Conditions
Explore the condition pages connected to this study.